GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy
Executive Summary
GlaxoSmithKline's proposed acquisition of ID Biomedical, announced Sept. 7, will bolster the drug maker's growing vaccine portfolio with the addition of Fluviral and several pipeline products
You may also be interested in...
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
Novartis Catches Flu Fever: Second Bid Nets Chiron
Novartis' first priority upon the completion of its acquisition of Chiron will be to resolve the flu vaccine maker's outstanding manufacturing issues, Novartis Head of Pharma Development Jörg Reinhardt said during an analyst call announcing the deal Oct. 31